97 related articles for article (PubMed ID: 8706041)
21. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
Glinsky GV; Price JE; Glinsky VV; Mossine VV; Kiriakova G; Metcalf JB
Cancer Res; 1996 Dec; 56(23):5319-24. PubMed ID: 8968076
[TBL] [Abstract][Full Text] [Related]
23. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
27. Gonadotropin-releasing hormone (GnRH) analogues and the ovary: do GnRH antagonists destroy primordial follicles?
Gupta RK; Flaws JA
Fertil Steril; 2005 May; 83(5):1339-42. PubMed ID: 15866566
[TBL] [Abstract][Full Text] [Related]
28. Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts.
Jacobs E; Watson SA; Michaeli D; Ellis IO; Robertson JF
Br J Cancer; 1999 May; 80(3-4):352-9. PubMed ID: 10408837
[TBL] [Abstract][Full Text] [Related]
29. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
30. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
[TBL] [Abstract][Full Text] [Related]
31. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists.
Danforth DR; Arbogast LK; Friedman CI
Fertil Steril; 2005 May; 83(5):1333-8. PubMed ID: 15866565
[TBL] [Abstract][Full Text] [Related]
32. Novel gonadotropin-releasing hormone antagonists with substitutions at position 5.
Samant MP; Hong DJ; Croston G; Rivier C; Rivier J
Biopolymers; 2005; 80(2-3):386-91. PubMed ID: 15614806
[TBL] [Abstract][Full Text] [Related]
33. Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma.
Bitonti AJ; Baumann RJ; Bush TL; Cashman EA; Wright CL; Prakash NJ
Anticancer Res; 1996; 16(5A):2553-7. PubMed ID: 8917350
[TBL] [Abstract][Full Text] [Related]
34. Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action.
Ratcliffe KE; Fraser HM; Sellar R; Rivier J; Millar RP
Endocrinology; 2006 Jan; 147(1):571-9. PubMed ID: 16223868
[TBL] [Abstract][Full Text] [Related]
35. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
36. Anticancer activity of a new gonadotropin releasing hormone analogue.
Saleh-Abady MM; Naderi-Manesh H; Alizadeh A; Shamsipour F; Balalaie S; Arabanian A
Biopolymers; 2010; 94(3):292-7. PubMed ID: 19908246
[TBL] [Abstract][Full Text] [Related]
37. Long-term inhibition of ovulation by a GnRH-antagonist at low dose level.
Kovacs M; Mezo I; Flerko B; Teplan I; Nikolics K
Biochem Biophys Res Commun; 1984 Jan; 118(1):351-5. PubMed ID: 6365100
[TBL] [Abstract][Full Text] [Related]
38. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.
Manea M; Tóvári J; Tejeda M; Schulcz A; Kapuvári B; Vincze B; Mezo G
Anticancer Drugs; 2012 Jan; 23(1):90-7. PubMed ID: 21915040
[TBL] [Abstract][Full Text] [Related]
39. [Pituitary gonadotropin releasing hormone (GnRH) and breast cancer].
Vargas Hernández VM; Moctezuma Espinosa J
Ginecol Obstet Mex; 1995 Dec; 63():493-6. PubMed ID: 8586292
[TBL] [Abstract][Full Text] [Related]
40. Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4.
Manea M; Leurs U; Orbán E; Baranyai Z; Öhlschläger P; Marquardt A; Schulcz Á; Tejeda M; Kapuvári B; Tóvári J; Mezo G
Bioconjug Chem; 2011 Jul; 22(7):1320-9. PubMed ID: 21668011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
